Jeremy Grantham's HRMY Position Overview
Jeremy Grantham (via Grantham, Mayo, Van Otterloo & Co. LLC) currently holds 11,182 shares of Harmony Biosciences Holdings, Inc. (HRMY) worth $313,208, representing 0.00% of the portfolio. First purchased in 2025-Q4, this recently established position has been held for 2 quarters.
Based on recent 13F filings, Jeremy Grantham has initiated a new position in HRMY, representing a fresh investment thesis on this company. Largest addition occurred in Q1 2026, adding 5,811 shares.
Analysis based on 13F filings available since 2013 Q2
Jeremy Grantham's Harmony Biosciences Holdings (HRMY) Holding Value Over Time
Track share changes against reported price movement
Quarterly Harmony Biosciences Holdings (HRMY) Trades by Jeremy Grantham
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +5,811 | Add 108.19% | 11,182 | $28.01 |
| Q4 2025 | +5,371 | New Buy | 5,371 | $37.42 |
Jeremy Grantham's Harmony Biosciences Holdings Investment FAQs
Jeremy Grantham first purchased Harmony Biosciences Holdings, Inc. (HRMY) in Q4 2025, acquiring 5,371 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeremy Grantham has held Harmony Biosciences Holdings, Inc. (HRMY) for 2 quarters since Q4 2025.
Jeremy Grantham's largest addition to Harmony Biosciences Holdings, Inc. (HRMY) was in Q1 2026, adding 11,182 shares worth $313,208.
According to the latest 13F filing for Q1 2026, Jeremy Grantham's firm, Grantham, Mayo, Van Otterloo & Co. LLC, owns 11,182 shares of Harmony Biosciences Holdings, Inc. (HRMY), valued at approximately $313,208.
As of the Q1 2026 filing, Harmony Biosciences Holdings, Inc. (HRMY) represents approximately 0.00% of Jeremy Grantham's publicly disclosed stock portfolio, making it one of their key holdings.
Jeremy Grantham's peak holding in Harmony Biosciences Holdings, Inc. (HRMY) was 11,182 shares, as reported at the end of Q1 2026.